3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lung Neoplasms
3
Thrombosis
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Esophageal Squamous Cell Carcinoma
2
Disease
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombophilia
1
Thrombocytopenia
1
Thoracic Neoplasms
1
Skin Neoplasms
1
Pituitary Neoplasms
1
Pediatric Solid Tumor, Unspecified, Protocol Specific
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
22
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
15
Papillomavirus Vaccines
9
Vaccines
6
Blood Specimen Collection
4
Watchful Waiting
2
Vaccines, Synthetic
2
Light Coagulation
2
Hepatitis A Vaccines
2
Engerix-B
2
lime
1
halofantrine
1
Sodium Chloride
1
Radiotherapy, Intensity-Modulated
1
Pentetic Acid
1
Olive Oil
1
Observation
1
Measles-Mumps-Rubella Vaccine
1
Laser Therapy
1
Injections
1
Imiquimod
1
Human Papillomavirus DNA Tests
1
Fluorouracil
1
Diphtheria-Tetanus-acellular Pertussis Vaccines
1
DTPa-HBV-IPV combined vaccine
1
Colposcopy
1
Clinical Protocols
1
Cisplatin
1
Circumcision, Male
1
Chorionic Villi Sampling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Papillomavirus Infections
×
Injections
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled